GP1a
Based on 1 publication(s) in Google Scholar
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.
For research use only. We do not sell to patients.
- Purity : 99.69%
- CAS No.: 511532-96-0
- Formula: C23H22Cl2N4O
- Molecular Weight:441.35
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) GP1a
More
Biological Activity
Description
Chemical Information
-
CAS No. 511532-96-0
-
Appearance Solid
-
Molecular Weight 441.35
-
Formula C23H22Cl2N4O
-
Color White to off-white
-
SMILES
O=C(C1=NN(C2=C(C=C(Cl)C=C2)Cl)C3=C1CC4=CC(C)=CC=C34)NN5CCCCC5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (283.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2658 mL | 11.3289 mL | 22.6578 mL | 56.6444 mL |
| 5 mM | 0.4532 mL | 2.2658 mL | 4.5316 mL | 11.3289 mL | |
| 10 mM | 0.2266 mL | 1.1329 mL | 2.2658 mL | 5.6644 mL | |
| 15 mM | 0.1511 mL | 0.7553 mL | 1.5105 mL | 3.7763 mL | |
| 20 mM | 0.1133 mL | 0.5664 mL | 1.1329 mL | 2.8322 mL | |
| 25 mM | 0.0906 mL | 0.4532 mL | 0.9063 mL | 2.2658 mL | |
| 30 mM | 0.0755 mL | 0.3776 mL | 0.7553 mL | 1.8881 mL | |
| 40 mM | 0.0566 mL | 0.2832 mL | 0.5664 mL | 1.4161 mL | |
| 50 mM | 0.0453 mL | 0.2266 mL | 0.4532 mL | 1.1329 mL | |
| 60 mM | 0.0378 mL | 0.1888 mL | 0.3776 mL | 0.9441 mL | |
| 80 mM | 0.0283 mL | 0.1416 mL | 0.2832 mL | 0.7081 mL | |
| 100 mM | 0.0227 mL | 0.1133 mL | 0.2266 mL | 0.5664 mL |